Home Sleep Apnea Testing Devices Market Size By Test Type (Type 2, Type 3, Type 4), Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2022

Description

List of Tables

The home sleep apnea testing devices market size is projected to grow substantially by 2030 driven by escalating geriatric population worldwide. Sleep-related breathing disorders like obstructive and central sleep apnea are more common among the elderly. Alcohol consumption, obesity, and smoking are also some of the contributors to sleep apnea. Elderly patients suffering from sleep apnea are also more prone to other medical disorders such as myocardial infarction, congestive heart failure, and stroke.

According to the World Health Organization (WHO), the global geriatric population is expected to double by 2050. Additionally, the elderly population aged above 60 years is expected to witness threefold growth by 2050, reaching about 1.3 billion.

Several industry players are foraying into strategic partnerships and expansions to ramp up the innovation of sleep apnea testing and treatment. In August 2022, ResMed acquired German digital solutions provider Mementor to expand its overall sleep portfolio in Germany with a digital solution for insomnia. ResMed also unveiled its new technology R&D center in Sandyford, Dublin alongside plans to scale up the performance of its Ireland-based unit.

Meanwhile, various new entities in the home sleep apnea testing devices industry are introducing groundbreaking technologies. For instance, in May 2022, Sunrise, a Belgian sleep tech company, launched a lightweight and user-friendly at-home sleep test.

In November 2021, Acurable, a UK-based medical device company, received FDA approval for its AcuPebble SA100, a compact wearable device that enables automated remote home testing of obstructive sleep apnea.

The global home sleep apnea testing devices industry is bifurcated into test type and region.

With respect to test type, the industry is fragmented into type 2, type 3, and type 4. In 2021, the type 4 segment held more than 24% of the market share and is expected to reach over USD 828 million by 2030. Type 4 home sleep apnea testing devices ensure precise disease diagnosis and help assess the treatment efficacy.

In the regional landscape, the Asia Pacific home sleep apnea testing devices market size is estimated to value more than USD 872 million by 2030. APAC is home to a massive geriatric population base and represents a considerable share of sleep apnea and other sleep disorders. Rapid privatization of the healthcare sector and medical tourism will favor businesses operating in the home sleep apnea testing devices space in the region.

Developing economies of APAC are boosting health insurance penetration along with advancements in remote and at-home healthcare. In 2021, the World Bank granted $40 million worth of funding to the Meghalaya Health Systems Strengthening Project in India. The project is established to expand health insurance coverage in the state, provide better quality health services and facilitate access to diagnostics and medicines.

Product Code: 4439

Chapter 1 Methodology & Scope

1.1 Market definitions
1.2 Base estimates and working
1.3 Forecast parameters
1.4 Data validation
1.5 Data sources
- 1.5.1 Secondary
  - 1.5.1.1 Paid sources
  - 1.5.1.2 Unpaid sources
- 1.5.2 Primary

Chapter 2 Executive Summary

2.1 Home sleep apnea testing devices industry 360 degree synopsis, 2017 - 2030
- 2.1.1 Business trends
- 2.1.2 Test type trends
- 2.1.3 Regional trends

Chapter 3 Home Sleep Apnea Testing Devices Industry Insights

3.1 Industry segmentation
3.2 Industry landscape, 2017 - 2030 (USD Million)
3.3 Industry impact forces
- 3.3.1 Growth drivers
  - 3.3.1.1 Growing prevalence of sleep apnea and related co-morbidities
  - 3.3.1.2 Increasing awareness regarding home sleep apnea tests
  - 3.3.1.3 Increasing aging population
  - 3.3.1.4 Product innovation strategy adopted by key industry players
- 3.3.2 Industry pitfalls & challenges
  - 3.3.2.1 Clinical consequences and economic impact of sleep apnea and related sleep disorders
  - 3.3.2.2 Stringent regulations
3.4 Growth potential analysis
- 3.4.1 By test type
3.5 COVID-19 impact analysis
3.6 Regulatory landscape
3.7 Reimbursement scenario
3.8 Technological landscape
3.9 Porter's analysis
3.10 Competitive landscape, 2021
- 3.10.1 Competitive matrix analysis, 2021
3.11 PESTEL analysis

Chapter 4 Home Sleep Apnea Testing Devices Market, By Test Type

4.1 Key segment trends
4.2 Type 2
- 4.2.1 Market size, by region, 2017 - 2030 (USD Million)
4.3 Type 3
- 4.3.1 Market size, by region, 2017 - 2030 (USD Million)
4.4 Type 4
- 4.4.1 Market size, by region, 2017 - 2030 (USD Million)

Chapter 5 Home Sleep Apnea Testing Devices Market, By Region

5.1 Key regional trends
5.2 North America
- 5.2.1 Market size, by country, 2017 - 2030 (USD Million)
- 5.2.2 Market size, by test type, 2017 - 2030 (USD Million)
- 5.2.3 U.S.
  - 5.2.3.1 Market size, by test type, 2017 - 2030 (USD Million)
- 5.2.4 Canada
  - 5.2.4.1 Market size, by test type, 2017 - 2030 (USD Million)
5.3 Europe
- 5.3.1 Market size, by country, 2017 - 2030 (USD Million)
- 5.3.2 Market size, by test type, 2017 - 2030 (USD Million)
- 5.3.3 Germany
  - 5.3.3.1 Market size, by test type, 2017 - 2030 (USD Million)
- 5.3.4 UK
  - 5.3.4.1 Market size, by test type, 2017 - 2030 (USD Million)
- 5.3.5 France
  - 5.3.5.1 Market size, by test type, 2017 - 2030 (USD Million)
- 5.3.6 Spain
  - 5.3.6.1 Market size, by test type, 2017 - 2030 (USD Million)
- 5.3.7 Italy
  - 5.3.7.1 Market size, by test type, 2017 - 2030 (USD Million)
5.4 Asia Pacific
- 5.4.1 Market size, by country, 2017 - 2030 (USD Million)
- 5.4.2 Market size, by test type, 2017 - 2030 (USD Million)
- 5.4.3 China
  - 5.4.3.1 Market size, by test type, 2017 - 2030 (USD Million)
- 5.4.4 Japan
  - 5.4.4.1 Market size, by test type, 2017 - 2030 (USD Million)
- 5.4.5 India
  - 5.4.5.1 Market size, by test type, 2017 - 2030 (USD Million)
- 5.4.6 Australia
  - 5.4.6.1 Market size, by test type, 2017 - 2030 (USD Million)
- 5.4.7 South Korea
  - 5.4.7.1 Market size, by test type, 2017 - 2030 (USD Million)
5.5 Latin America
- 5.5.1 Market size, by country, 2017 - 2030 (USD Million)
- 5.5.2 Market size, by test type, 2017 - 2030 (USD Million)
- 5.5.3 Brazil
  - 5.5.3.1 Market size, by test type, 2017 - 2030 (USD Million)
- 5.5.4 Mexico
  - 5.5.4.1 Market size, by test type, 2017 - 2030 (USD Million)
- 5.5.5 Argentina
  - 5.5.5.1 Market size, by test type, 2017 - 2030 (USD Million)
5.6 Middle East and Africa
- 5.6.1 Market size, by country, 2017 - 2030 (USD Million)
- 5.6.2 Market size, by test type, 2017 - 2030 (USD Million)
- 5.6.3 South Africa
  - 5.6.3.1 Market size, by test type, 2017 - 2030 (USD Million)
- 5.6.4 Saudi Arabia
  - 5.6.4.1 Market size, by test type, 2017 - 2030 (USD Million)
- 5.6.5 UAE
  - 5.6.5.1 Market size, by test type, 2017 - 2030 (USD Million)

Chapter 6 Company Profiles

6.1 Competitive dashboard, 2021
6.2 Compumedics Limited
- 6.2.1 Business overview
- 6.2.2 Financial data
- 6.2.3 Product landscape
- 6.2.4 Strategic outlook
- 6.2.5 SWOT analysis
6.3 Cadwell Laboratories Inc.
- 6.3.1 Business overview
- 6.3.2 Financial data
- 6.3.3 Product landscape
- 6.3.4 Strategic outlook
- 6.3.5 SWOT analysis
6.4 CleveMed
- 6.4.1 Business overview
- 6.4.2 Financial data
- 6.4.3 Product landscape
- 6.4.4 Strategic outlook
- 6.4.5 SWOT analysis
6.5 Contec Medical Systems
- 6.5.1 Business overview
- 6.5.2 Financial data
- 6.5.3 Product landscape
- 6.5.4 Strategic outlook
- 6.5.5 SWOT analysis
6.6 Itamar Medical Inc.
- 6.6.1 Business overview
- 6.6.2 Financial data
- 6.6.3 Product landscape
- 6.6.4 Strategic outlook
- 6.6.5 SWOT analysis
6.7 Koninklijke Philips N.V.
- 6.7.1 Business overview
- 6.7.2 Financial data
- 6.7.3 Product landscape
- 6.7.4 Strategic outlook
- 6.7.5 SWOT analysis
6.8 Natus Medical Inc.
- 6.8.1 Business overview
- 6.8.2 Financial data
- 6.8.3 Product landscape
- 6.8.4 Strategic outlook
- 6.8.5 SWOT analysis
6.9 Neurosoft
- 6.9.1 Business overview
- 6.9.2 Financial data
- 6.9.3 Product landscape
- 6.9.4 Strategic outlook
- 6.9.5 SWOT analysis
6.10 NeuroVirtual/SleepVirtual
- 6.10.1 Business overview
- 6.10.2 Financial data
- 6.10.3 Product landscape
- 6.10.4 Strategic outlook
- 6.10.5 SWOT analysis
6.11 Nihon Kohden Corporation
- 6.11.1 Business overview
- 6.11.2 Financial data
- 6.11.3 Product landscape
- 6.11.4 Strategic outlook
- 6.11.5 SWOT analysis
6.12 Nox Medical
- 6.12.1 Business overview
- 6.12.2 Financial data
- 6.12.3 Product landscape
- 6.12.4 Strategic outlook
- 6.12.5 SWOT analysis
6.13 Resmed
- 6.13.1 Business overview
- 6.13.2 Financial data
- 6.13.3 Product landscape
- 6.13.4 Strategic outlook
- 6.13.5 SWOT analysis
6.14 SleepMed
- 6.14.1 Business overview
- 6.14.2 Financial data
- 6.14.3 Product landscape
- 6.14.4 Strategic outlook
- 6.14.5 SWOT analysis
6.15 SOMNOmedics GmbH
- 6.15.1 Business overview
- 6.15.2 Financial data
- 6.15.3 Product landscape
- 6.15.4 Strategic outlook
- 6.15.5 SWOT analysis